Development of Specific Antibodies to an ARF Protein in Treated Patients with Chronic HCV Infection

Cohen, Michal; Bachmatov, Larisa; Ben‐Ari, Ziv; Rotman, Yaron; Tur–Kaspa, Ran; Zemel, Romy

doi:10.1007/s10620-006-9630-2

Cited by 28 publications

(44 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, to investigate the lack of cross reactivity between core and F some samples were tested for both Core and F antibody in which there were some samples reacting with Core without any significant detection of F antibody (data not shown). The seroprevalence of anti-F antibodies in our study is in accordance with the results reported by Cohen et al who investigated specific anti-F antibodies in 89% of the 1b hepatitis C patients in Israel (18), but are higher than those reported by Miladi et al who observed anti-F antibodies only in an estimated 10% of HCV patients infected with genotype 1b in France (17). To our knowledge there is only one report of 62% seroprevalance of anti F in 1a chronically infected patients in France (20).…”

Section: Discussionsupporting

confidence: 92%

“…Among the HCV proteins, NS5A, E2, and NS3 have been shown to interfere with IFN-α or -β treatment, causing antiviral resistance (16,24). The HCV core protein perturbs the function of cellular proteins involved in T-cell proliferation and induces apoptosis, thereby leading to immune suppression and liver damage (18). Our results confirm the expression of F protein during natural HCV infection, but the role of F protein in the HCV life cycle and the significance of anti-F antibodies in chronic HCV infection have yet to be elucidated.…”

Section: Discussionsupporting

confidence: 63%

“…HCV F protein is a newly identified HCV gene product that is produced from the core encoding region by a translational ribosomal frame shift (18). For HCV genotype 1a-derived ARFP, the frameshifting occurs at codons 9 to 11 of the core protein sequence (19).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Development of a Recombinant Based ELISA using Specific Antibodies to F Protein in HCV Chronically Infected Patients-A Seroprevalence Study

et al. 2010

View full text Add to dashboard Cite

Background and Aims: The hepatitis C virus (HCV) F protein is a recently described, frameshift product of HCV core encoding sequence. Its function and antigenic properties are unknown. In order to assess the presence of antibodies specific for F protein we characterized specific anti-F antibodies in patients with chronic HCV infection. Methods: The F protein was cloned from the HCV genome. The recombinant protein was expressed in Escherichia coli and purified by immunoaffinity chromatography. An enzymelinked immunosorbent assay was developed using the purified recombinant HCV F protein.Results: Serum samples were collected from 72 patients with chronic HCV infection and from 30 healthy controls. Eighty-two percent of chronic HCV patients had evidence of anti-F antibodies. 59 samples out of the 72 HCV infected patients exhibited a positive anti-F reaction, showing significant difference from the controls with no HCV infection (P < 0.01). Conclusion: Based on these findings, HCV F protein elicits a specific antibody response, so frameshift could occur in the core-coding sequence in HCV genotype 1a in Iranian patients. As the first report, the prevalence of anti-F antibodies in chronic hepatitis C in Iran is of the order of 82%.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 63%

See 1 more Smart Citation

Development of a Recombinant Based ELISA using Specific Antibodies to F Protein in HCV Chronically Infected Patients-A Seroprevalence Study

et al. 2010

View full text Add to dashboard Cite

show abstract

“…HCV is one of the leading causes of persistent infection in humans that can predispose to liver fibrosis and cirrhosis. There are some reports indicating that chronic hepatitis C (CHC) infection is strongly associated with hepatocellular carcinoma (HCC) (3)(4)(5)(6)(7)(8)(9). There is neither effective vaccine for immunization, nor a broadly effective treatment for HCV infection (3).Among different factors associated with chronic HCV infection, alternate reading frame protein (ARFP) or core+1 protein is one the newest ones that can promote persistent infection (10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

“…It is shown that core+1 protein interacts with p21, leading to inhibition of the cell cycle (16). Cohen et al, (5) suggested no significant correlation between the presence of anti-core+1 antibody (Ab) and HCV viremia or antiviral therapy outcome, while Gao et al, (17) found a correlation between anti-core+1 Ab and the outcome of treatment in patients infected with HCV. Many studies suggested the critical role of core+1 protein in humoral response, HCV infection status (12,18) as well as outcomes (11, Copyright © 2018, Jundishapur Journal of Microbiology.…”

Section: Introductionmentioning

confidence: 99%

A Decline in Anti-Core+1 Antibody Titer Occurs in Successful Treatment of Patients Infected with Hepatitis C Virus

Hashempoor¹,

Alborzi²,

Moayedi³

et al. 2018

Jundishapur J Microbiol

View full text Add to dashboard Cite

Background: Hepatitis C virus (HCV) causes one of the major chronic liver diseases (CLD). HCV-core encoding sequence possesses an overlapping open reading frame (ORF) that expresses a protein called F or core+1. Objectives: The current study aimed at assessing the presence and titer of anti-core+1 antibody (Ab) in 70 Iranian patients infected with HCV-1a, responder and non-responder groups, under combination therapy with pegylated interferon-α (PegIFN-α) plus ribavirin (RBV) using an enzyme-linked immunosorbent assay (ELISA). Methods: In the current cohort study, HCV-1a core+1 gene was amplified and cloned into vector followed by expressing in Escherichia coli and then, purified by ion exchange chromatography. The antibody titer of patients was evaluated before, during (12, 24, and 48 weeks), and 6 months after the end of therapy (ETR). Results: The seroprevalence of anti-core+1 Ab was 75.7% in pretreatment sera. The combination therapy could induce a decline in the level of anti-core+1 Ab in both groups of responders and non-responders. These changes were significant only in the responders (P = 0.003). The seroprevalence of anti-core+1 Ab had no correlation with the outcome of treatment. Conclusions: According to the current study results, HCV core+1 protein elicit a specific antibody response other than the anti-core protein antibodies. The current study data also suggested that the level of anti-core+1 antibody might be affected by the combination therapy and associated with sustained virological response (SVR). The data implied that the declining trend of anti-core+1 Abs during the treatment might be an alternative representation of the therapeutic response in Iranian population infected with HCV.

show abstract

The HCV ARFP/F/core+1 protein: Production and functional analysis of an unconventional viral product

Vassilaki

Mavromara

2009

IUBMB Life

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is an enveloped positive‐strand RNA virus of the Flaviviridae family. It has a genome of about 9,600 nucleotides encoding a large polyprotein (about 3,000 amino acids) that is processed by cellular and viral proteases into at least 10 structural and nonstructural viral proteins. A novel HCV protein has also been identified by our laboratory and others. This protein—known as ARFP (alternative reading frame protein), F (for frameshift) or core+1 (to indicate the position) protein ‐ is synthesized by an open reading frame overlapping the core gene at nucleotide +1 (core+1 ORF). However, almost 10 years after its discovery, we still know little of the biological role of the ARFP/F/core+1 protein. Abolishing core+1 protein production has no affect on HCV replication in cell culture or uPA‐SCID mice, suggesting that core+1 protein is probably not important for the HCV reproductive cycle. However, the detection of specific anti‐core+1 antibodies and T‐cell responses in HCV‐infected patients, as reported by many independent laboratories, provides strong evidence that this protein is produced in vivo. Furthermore, analyses of the HCV sequences isolated from patients with hepatocellular carcinoma and in vitro studies have provided strong preliminary evidence to suggest that core+1 protein plays a role in advanced liver disease and liver cancer. The available in vitro data also suggest that certain core function proteins may depend on production of the core+1 protein. We describe here the discovery of the various forms of the core+1 protein and what is currently known about the mechanisms of their production and their biochemical and functional properties. We also provide a detailed summary of the results of patient‐based research. © 2009 IUBMB IUBMB Life, 61(7): 739–752, 2009

show abstract

Development of Specific Antibodies to an ARF Protein in Treated Patients with Chronic HCV Infection

Cited by 28 publications

References 21 publications

Development of a Recombinant Based ELISA using Specific Antibodies to F Protein in HCV Chronically Infected Patients-A Seroprevalence Study

Development of a Recombinant Based ELISA using Specific Antibodies to F Protein in HCV Chronically Infected Patients-A Seroprevalence Study

A Decline in Anti-Core+1 Antibody Titer Occurs in Successful Treatment of Patients Infected with Hepatitis C Virus

The HCV ARFP/F/core+1 protein: Production and functional analysis of an unconventional viral product

Contact Info

Product

Resources

About